DuPont Nutrition & Health recently presented on the latest developments on clinical research, market insights and trends on global probiotics products at the 3rd Probiotics and Health Medical Science Summit. Top food safety and clinical experts in China exchanged the standards and safety of probiotics and domestic clinical research results with focus on digestion, immunity, womens and childrens health, and internal microbiota regulation. The summit attracted close to 50 chief physicians from the Department of Gastroenterology, Nutrition, Dermatology, Endocrinology and Internal Medicine of leading Third-Level Grade-A hospitals across the country.

Megan DeStefano, Global Marketing Manager, Probiotics, DuPont Nutrition & Health said, “Through participating in seminars and scientific health conferences, DuPont hopes to infuse probiotics in clinical medicine and promote the wide range of benefits and applications it has in health food and pharmaceutical applications."

The rise of global clinical researches on probiotics in the areas of digestive, immune and metabolic health are redefining the importance of a healthy gut flora in the human microbiome, the company said. Probiotics are now not only limited to food and dietary supplements formats but are also applicable in the pharmaceutical industry. With more than a century of expertise in dairy cultures, DuPont claims it is the only culture and probiotics supplier with an in-house nutrition and health research centre. Equipped with proprietary process and products, new state of the art facilities, along with strong local support in innovation, application, regulation and production, DuPont says it can help manufacturers produce high quality probiotics products and provide impeccable expertise to customers globally.

“DuPont is a global leader in the science, research and production of probiotics,” said Dr. Susan Jin, Product Line Leader, Probiotics, Cultures and Food Protection Ingredient, Asia Pacific, DuPont Nutrition & Health. “We will continue to maintain high potency, stability and efficacy of our HOWARU probiotic products, and provide in-depth clinical research support, while continuing to work closely with relevant institutions and companies. This will all be beneficial to the Chinese consumers and contribute towards the vision of ‘Healthy China 2030’.”